STOCK TITAN

Resale of 2,277,002 Rocket Lab (NASDAQ: RKLB) shares

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Rocket Lab Corporation filed a prospectus supplement covering the resale of up to 2,277,002 shares of its common stock. These shares were issued on April 14, 2026 in a private placement tied to Rocket Lab’s previously announced acquisition of Mynaric AG under a Stock Purchase Agreement dated September 25, 2025.

The filing notes that the prospectus supplement was made pursuant to the Stock Purchase Agreement and is part of Rocket Lab’s existing automatic shelf registration statement on Form S-3ASR. A legal opinion and related consent from Goodwin Procter LLP regarding the shares are included as exhibits.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Shares registered for resale 2,277,002 shares Common stock covered by prospectus supplement for selling stockholders
Share issuance date April 14, 2026 Date the 2,277,002 shares were issued in private placement
Stock Purchase Agreement date September 25, 2025 Original date of Mynaric AG Stock Purchase Agreement
prospectus supplement regulatory
"filed with the Securities and Exchange Commission a prospectus supplement to the prospectus included"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Form S-3ASR regulatory
"registration statement on Form S-3ASR filed with the SEC on March 11, 2025"
Form S-3ASR is a type of SEC registration that lets large, well-known public companies pre-register securities so they can be sold quickly when needed, similar to having a pre-approved credit line they can draw on at short notice. For investors, it matters because it signals a company's readiness to raise cash fast, which can affect share supply and price (dilution) and reveal how easily the company can fund growth or handle short-term needs.
resale financial
"covering the resale by certain selling stockholders of up to 2,277,002 shares"
Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.
private placement financial
"shares of the Company’s Common Stock in the aggregate issued on April 14, 2026 in a private placement"
A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.
Stock Purchase Agreement financial
"pursuant to a Stock Purchase Agreement, dated as of September 25, 2025"
A stock purchase agreement is a legal contract that sets the terms for buying or selling shares, specifying the price, number of shares, how payment is made, and any conditions or promises each side must meet. It matters to investors because it defines who owns what, when ownership changes, and what protections or obligations attach to the deal—think of it as a detailed receipt plus the house rules that determine the financial risks and benefits of the transaction.
false 0001819994 0001819994 2026-05-08 2026-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

     
 

 

FORM 8-K

     
 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 8, 2026

     
 

 

ROCKET LAB CORPORATION

(Exact name of Registrant as Specified in Its Charter)

     
 
     
Delaware 001-39560 39-2182599
(State or Other Jurisdiction
of Incorporation)
(Commission File Number) (IRS Employer
Identification No.)
     
3881 McGowen Street  
Long Beach, California   90808
(Address of Principal Executive Offices)   (Zip Code)
     

Registrant’s Telephone Number, Including Area Code: 714 465-5737

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

     
 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

                             

Title of each class
  Trading
Symbol(s)
 
Name of each exchange on which registered
Common Stock, par value $0.0001 per share   RKLB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

     
 

 

 

Item 8.01 Other Events.

 

On May 8, 2026, Rocket Lab Corporation (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement to the prospectus included in the Company’s registration statement on Form S-3ASR filed with the SEC on March 11, 2025 (File No. 333-285707), as amended by the Post-Effective Amendment No. 1 filed with the SEC on May 27, 2025 (the “Registration Statement”), covering the resale by certain selling stockholders of up to 2,277,002 shares of the Company’s Common Stock in the aggregate issued on April 14, 2026 in a private placement in connection with the previously announced acquisition of Mynaric AG, pursuant to a Stock Purchase Agreement, dated as of September 25, 2025, by and among the Company, Rocket Lab USA, Inc., OC III LVS LIII LP, CO Finance II LVS I LLC, Rocket Lab Germany GmbH via joinder dated April 13, 2026 and OC IV LVS VI LP via joinder dated April 13, 2026 (the “Stock Purchase Agreement”). The prospectus supplement was filed in accordance with the Stock Purchase Agreement. A copy of the legal opinion of Goodwin Procter LLP relating to the shares covered by the prospectus supplement is filed herewith as Exhibit 5.1, and is filed with reference to, and is hereby incorporated by reference in, the Registration Statement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

     
Exhibit
No.
  Description
   
5.1   Opinion of Goodwin Procter LLP.
   
23.1   Consent of Goodwin Procter LLP (included in Exhibit 5.1).
   
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       
      ROCKET LAB CORPORATION
       
Date: May 8, 2026 By: /s/ Adam Spice
      Adam Spice
Chief Financial Officer

 

 

FAQ

What did Rocket Lab (RKLB) disclose in this 8-K filing?

Rocket Lab disclosed it filed a prospectus supplement covering the resale of up to 2,277,002 common shares. These shares were previously issued in a private placement connected to the acquisition of Mynaric AG under an existing stock purchase agreement and registration statement.

How many Rocket Lab (RKLB) shares are covered by the new prospectus supplement?

The prospectus supplement covers the resale of up to 2,277,002 Rocket Lab common shares. These shares were issued on April 14, 2026 in a private placement related to the Mynaric AG acquisition, and are being registered for potential resale by certain selling stockholders.

What transaction is linked to the Rocket Lab (RKLB) resale registration?

The resale registration is linked to Rocket Lab’s acquisition of Mynaric AG. The 2,277,002 shares being registered for resale were issued in an April 14, 2026 private placement under a Stock Purchase Agreement originally dated September 25, 2025 with several related entities.

Which registration statement does Rocket Lab’s new prospectus supplement relate to?

The prospectus supplement relates to Rocket Lab’s automatic shelf registration statement on Form S-3ASR. That registration statement was filed on March 11, 2025 and later amended by Post-Effective Amendment No. 1 filed on May 27, 2025, and now covers these resale shares.

Filing Exhibits & Attachments

4 documents